87 related articles for article (PubMed ID: 20452225)
1. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.
Lamblin M; Dabbas B; Spingarn R; Mendoza-Sanchez R; Wang TT; An BS; Huang DC; Kremer R; White JH; Gleason JL
Bioorg Med Chem; 2010 Jun; 18(11):4119-37. PubMed ID: 20452225
[TBL] [Abstract][Full Text] [Related]
2. Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition.
Fischer J; Wang TT; Kaldre D; Rochel N; Moras D; White JH; Gleason JL
Chem Biol; 2012 Aug; 19(8):963-71. PubMed ID: 22921063
[TBL] [Abstract][Full Text] [Related]
3. Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids.
Kaldre D; Wang TT; Fischer J; White JH; Gleason JL
Bioorg Med Chem; 2015 Aug; 23(15):5035-5049. PubMed ID: 26048026
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer.
Bijian K; Kaldre D; Wang TT; Su J; Bouttier M; Boucher A; Alaoui-Jamali M; White JH; Gleason JL
J Steroid Biochem Mol Biol; 2018 Mar; 177():135-139. PubMed ID: 28847749
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.
Griffith D; Morgan MP; Marmion CJ
Chem Commun (Camb); 2009 Nov; (44):6735-7. PubMed ID: 19885462
[TBL] [Abstract][Full Text] [Related]
6. New signalling pathway involved in the anti-proliferative action of vitamin D₃ and its analogues in human neuroblastoma cells. A role for ceramide kinase.
Bini F; Frati A; Garcia-Gil M; Battistini C; Granado M; Martinesi M; Mainardi M; Vannini E; Luzzati F; Caleo M; Peretto P; Gomez-Muñoz A; Meacci E
Neuropharmacology; 2012 Sep; 63(4):524-37. PubMed ID: 22579669
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of a superagonist ligand for the vitamin D nuclear receptor.
Hourai S; Rodrigues LC; Antony P; Reina-San-Martin B; Ciesielski F; Magnier BC; Schoonjans K; Mouriño A; Rochel N; Moras D
Chem Biol; 2008 Apr; 15(4):383-92. PubMed ID: 18420145
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
Huang D; Li X; Sun L; Xiu Z; Nishino N
J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
[TBL] [Abstract][Full Text] [Related]
11. Novel A-ring homodimeric C-3-carbamate analogues of 1alpha,25-dihydroxyvitamin D3: synthesis and preliminary biological evaluation.
Oves D; Fernández S; Verlinden L; Bouillon R; Verstuyf A; Ferrero M; Gotor V
Bioorg Med Chem; 2006 Nov; 14(22):7512-9. PubMed ID: 16879968
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of bifunctional vitamin D receptor agonist-histone deacetylase inhibitor hybrid molecules in triple-negative breast cancer.
Barbier C; Mansour A; Ismailova A; Sarmadi F; Scarlata DA; Bouttier M; Zeitouni C; Wang C; Gleason JL; White JH
Sci Rep; 2022 Apr; 12(1):6745. PubMed ID: 35468986
[TBL] [Abstract][Full Text] [Related]
13. Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation.
Peleg S; Petersen KS; Suh BC; Dolan P; Agoston ES; Kensler TW; Posner GH
J Med Chem; 2006 Dec; 49(25):7513-7. PubMed ID: 17149880
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist.
Tavera-Mendoza LE; Quach TD; Dabbas B; Hudon J; Liao X; Palijan A; Gleason JL; White JH
Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8250-5. PubMed ID: 18550844
[TBL] [Abstract][Full Text] [Related]
15. 4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
Rossi C; Fincham CI; D'Andrea P; Porcelloni M; Ettorre A; Mauro S; Bigioni M; Binaschi M; Maggi CA; Nardelli F; Parlani M; Fattori D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6767-9. PubMed ID: 21978679
[TBL] [Abstract][Full Text] [Related]
16. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
Park H; Kim S; Kim YE; Lim SJ
ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
Charrier C; Roche J; Gesson JP; Bertrand P
Bioorg Med Chem Lett; 2007 Nov; 17(22):6142-6. PubMed ID: 17897824
[TBL] [Abstract][Full Text] [Related]
18. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
19. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.
Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
